Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 27, 2019 16:08 ET | Source: FibroGen, Inc

FibroGen Reports Fourth Quarter and Full Year 2018 Financial Results

—Roxadustat Approved in China for Anemia in Dialysis-Dependent CKD Patients— —Primary Efficacy Endpoints Met in Seven Phase 3 Roxadustat Studies for U.S./EU— —Conference Call Today at...
February 22, 2019 23:43 ET | Source: FibroGen, Inc

FibroGen Reports Fourth Quarter and Full Year 2018 Financial Results

SAN FRANCISCO, Feb. 22, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today...
December 20, 2018 07:00 ET | Source: FibroGen, Inc

FibroGen Announces Positive Topline Results from Three Global Phase 3 Trials of Roxadustat for Treatment of Anemia in Patients with Chronic Kidney Disease

SAN FRANCISCO, Dec. 20, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today...
December 17, 2018 18:07 ET | Source: FibroGen, Inc

FibroGen Announces Approval of Roxadustat in China for the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis

China is the first country to approve roxadustat First-in-class roxadustat offers a new, effective oral treatment SAN FRANCISCO, Dec. 17, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN)...
December 06, 2018 04:00 ET | Source: FibroGen, Inc

FibroGen Appoints Maykin Ho, Ph.D., to Board of Directors

SAN FRANCISCO, Dec. 06, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today...
November 08, 2018 16:02 ET | Source: FibroGen, Inc

FibroGen Reports Third Quarter 2018 Financial Results

—Roxadustat New Drug Applications under Review in China and Japan——Phase 3 Clinical Trials in IPF and Pancreatic Cancer to Initiate in First Quarter 2019——Conference Call Today at 5:00 p.m. Eastern...
November 02, 2018 17:02 ET | Source: FibroGen, Inc

FibroGen to Report Third Quarter 2018 Financial Results on Thursday, November 8, 2018

Conference Call and Audio Webcast Scheduled for 5:00 p.m. ET (2:00 p.m. PT) SAN FRANCISCO, Nov. 02, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a biopharmaceutical company, today...
October 30, 2018 04:00 ET | Source: FibroGen, Inc

ASN Kidney Week 2018: Data Presented from Two Japanese Phase 3 Studies on Roxadustat in the Treatment of Anemia Associated with Chronic Kidney Disease in Patients on Dialysis

TOKYO and SAN FRANCISCO, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and FibroGen, Inc. (Nasdaq: FGEN, CEO: Thomas B....
October 25, 2018 19:49 ET | Source: FibroGen, Inc

FibroGen Presents Results from Two Phase 3 Studies of Roxadustat for the Treatment of Anemia Associated with Chronic Kidney Disease Conducted in China at American Society of Nephrology Kidney Week 2018 Annual Meeting

SAN FRANCISCO, Oct. 25, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, and FibroGen...
October 16, 2018 16:27 ET | Source: FibroGen, Inc

FibroGen Announces Four Clinical Presentations on Roxadustat at Upcoming American Society of Nephrology Kidney Week 2018 Annual Meeting

Roxadustat Phase 3 Clinical Results in Late-Breaking Clinical Trial Posters and Oral Presentation SAN FRANCISCO, Oct. 16, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a leading...